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COSYCONETAbstract Chronic obstructive pulmonary disease (COPD) significantly increases the risk of devel-
oping cancer. Biomarker studies frequently follow a case-control set-up in which patients diagnosed
with a disease are compared to controls. Longitudinal cohort studies such as the COPD-centered
German COPD and SYstemic consequences-COmorbidities NETwork (COSYCONET) study pro-
vide the patient and biomaterial base for discovering predictive molecular markers. We asked
whether microRNA (miRNA) profiles in blood collected from COPD patients prior to a tumor diag-
nosis could support an early diagnosis of tumor development independent of the tumor type. From
2741 participants of COSYCONET diagnosed with COPD, we selected 534 individuals including 33
patients who developed cancer during the follow-up period of 54 months and 501 patients who did
not develop cancer, but had similar age, gender and smoking history. Genome-wide miRNA profiles
were generated and evaluated using machine learning techniques. For patients developing cancer we
identified nine miRNAs with significantly decreased abundance (two-tailed unpaired t-test adjusted
for multiple testing P< 0.05), including members of the miR-320 family. The identified miRNAs
regulate different cancer-related pathways including the MAPK pathway (P= 2.3  105). We also
observed the impact of confounding factors on the generated miRNA profiles, underlining the value
of our matched analysis. For selected miRNAs, qRT-PCR analysis was applied to validate the
results. In conclusion, we identified several miRNAs in blood of COPD patients, which could serve
as candidates for biomarkers to help identify COPD patients at risk of developing cancer.Introduction
Chronic obstructive pulmonary disease (COPD) is a common
disease that affects several hundred million people worldwide.
It represents one of the most common causes of death. Accord-
ing to the World Health Organization, in 2015, COPD is esti-
mated to have caused the death of 3.17 million patients (http://
who.int/mediacentre/factsheets/fs310/en/). COPD is consid-
ered a systemic disease and is often associated with comorbidi-
ties that have significant impact on the quality of life [1].
Patients suffering from COPD have also an increased risk of
cancer [2]. In particular, COPD increases the risk of develop-
ing lung cancer significantly [3].
The underlying mechanisms of the increased cancer risk in
COPD patients are unclear but probably involve the presence
of chronic inflammation, increased levels of oxidative stress
leading to DNA damage, exposure to cytokines that repress
the DNA repair mechanisms [3], and the changes of the pul-
monary microbiota [4]. Specifically, the activation of NF-jB
plays an important role in the development of lung cancer
from COPD [5]. In addition, COPD patients have an increased
risk of a worse outcome after lung cancer diagnosis and treat-
ment [6]. In sum, there is growing evidence suggesting a close
association between persistent chronic inflammation and lung
cancer [7] and even evidence for a causal relationship between
inflammation and lung cancer [8]. Consequently, early diagno-
sis of lung cancer is of exceptional importance for individuals
affected by COPD. Hence, there is a clinical need for biomark-
ers that indicate an increased risk of cancer development in
COPD patients.
Lung cancer is, however, not the only cancer comorbidity
in COPD patients. Several cohort studies revealed an increased
risk of other, mostly tobacco-related cancers. A nationwide
Danish study shows increased incidences for cancers of the
lung, larynx, tongue, oral cavity, pharynx, esophagus, stom-
ach, liver, pancreas, cervix uteri, and urinary tract in COPD
patients, with standardized incidence ratios between 1.3-fold
and 2.8-fold [9]. Similar results have also been reported in anationwide cohort study in Taiwan showing a 2.8-fold increase
in hazard ratio of COPD patients for developing cancers as
compared to controls without COPD after adjusting for age,
sex and comorbidities [2]. The most common cancers reported
in this study are lung, liver, colorectal, breast, prostate, and
stomach cancers [9].
Besides the consumption of tobacco as the most common
cause of COPD, age is an important risk factor for COPD
[10]. Moreover, a number of single nucleotide variants (SNVs)
in the genome are known to be associated with COPD [11–13].
Besides single nucleotide polymorphisms (SNPs) in protein-
coding genes, SNPs in RNAs that are not transcribed seem
to play a role in the development of COPD as well [14,15].
One important class, belonging to the small non-coding RNAs
(sncRNAs), comprises microRNAs (miRNAs) that are 21–23
nucleotides in length. Several studies have reported tissue-
based miRNA profiles or circulating miRNA profiles in COPD
[16,17]. Studies aiming at biomarker discovery and/or valida-
tion provide the first evidence for miRNAs as potential mark-
ers for lung cancer [18–20] and other tumor types [21].
miRNAs have also been discussed as regulators of airborne
pollution-induced lung inflammation and carcinogenesis [22].
Some miRNAs are not linked to one single cancer type, but
may be dysregulated in multiple cancer types or even in dis-
eases in general, such as miR-144 [23]. A substantial fraction
of miRNA lung biomarker studies rely on case–control set-
ups where diseased patients are compared with a control
cohort of unaffected individuals or with patients suffering
from diseases with similar symptoms [24].
Being aware of both the promises and challenges of miR-
NAs for a future diagnostic applications in general [25] and
for lung cancer specifically [26], we asked whether blood-
based miRNA signatures of COPD patients who develop can-
cer within a given time window, are different from COPD
patients who do not develop cancer. To answer this question,
a large set of COPD patients who have been followed up for
several years is required for the identification of cancer-
predictive miRNA profiles. The German COPD and SYstemic
Table 1 COPD patient characteristics
Cohort 1 Cohort 2
Statistical
significance
Gender (female/male) 179/322 8/25 n.s.
Smoker (never/past/present) 21/358/122 1/28/4 n.s.
Age (mean ± sd) 67 ± 7.8 69 ± 5.9 n.s.
Packyears (mean ± sd) 47 ± 36.7 61 ± 37.8 n.s.
Note: n.s., not significant.
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study has collected biomaterial and clinical information of
COPD patients with a follow-up time of 54 months [27].
The study set-up allows us to compare molecular baseline
measurements with clinical parameters. We are also able to
investigate whether the COPD patients who did not have
cancer diagnosis at baseline, but with cancer developed over
time, show molecular patterns associated with the develop-
ment of cancer.
Results
The study set-up is sketched in Figure 1. We analyzed genome-
wide miRNA profiles for 2549 mature human miRNAs of
blood samples collected from 534 COPD patients participating
in the COSYCONET study. Details on the patient cohorts
including age, gender, and smoking status are provided in
Table 1.
Nine significant miRNAs predict the development of cancer
We compared miRNA expression profiles in patients not
developing cancer (n = 501; Cohort 1 in Table 1) to those
developing cancer (n = 33; Cohort 2 in Table 1) within a
follow-up period of up to 54 months. Out of the 2549 profiled
miRNAs, 269 (10.6%) were nominally significant (i.e., unad-
justed P< 0.05; t-test), including 199 showing decreased
expression and 70 showing increased expression in patients
developing cancer. Although the number of features, i.e., miR-
NAs in this study (P= 2549), as measured in the study wasFigure 1 Experimental design
We profiled individuals with COPD (blue) who either did not develop
month follow-up. Genome-wide blood-borne miRNA profiles were ge
with clinical data from the COSYCONET data repository using statist
COPD, chronic obstructive pulmonary disease; COSYCONET, COPDsubstantially above the total cohort size (n = 534), nine miR-
NAs still remained statistically significant after adjustment for
multiple testing using the Benjamini–Hochberg approach.
These include hsa-miR-548d-5p, hsa-miR-4695-3p, hsa-miR-
517a-3p, hsa-miR-4785, hsa-miR-7109-3p, hsa-miR-320e,
hsa-miR-548ay-5p, hsa-miR-320c, and hsa-miR-519d-3p. In
accordance with the observation that the expression of most
miRNAs in patients developing cancer was reduced, all of
these nine miRNAs showed a decreased abundance as well.
An overview of the miRNA expression is presented as Volcano
plot in Figure 2, showing the negative log10 P value versus the
log2 fold change of the miRNA. Besides the parametric t-test,
we also applied the non-parametric Wilcoxon–Mann–Whitney
test. Both tests showed a high concordance (Pearson correla-
tion of 0.76, P< 1016), although none of the miRNAs
remained significant following adjustment for multiple testing
in this rank-based test. A complete list of raw and adjusted
P values for both hypothesis tests is provided for all 2549 miR-
NAs in Table S1, together with the median expression of each
miRNA in the two cohorts and the respective fold change.cancer (Cohort 1) or developed cancer (Cohort 2) during the 54-
nerated for all 534 patients. These expression data were correlated
ical approaches implemented in the programming environment R.
and SYstemic consequences-COmorbidities NETwork.
Figure 2 Volcano plots for the pair-wise comparison of patients
developing cancer and patients not developing cancer
Volcano plots show on the Y-axis the negative log10 P value of the
t-test and on the Y-axis the log2 fold change. Green dots indicate
miRNAs with higher expression in blood samples from Cohort 1,
while red dots represent miRNAs with higher expression in blood
samples from Cohort 2 according to the raw P< 0.05. All dots
with raw P  0.05 are colored in gray. The horizontal blue line
separates miRNAs that are significant following Benjamini–
Hochberg adjustment (above the line; adjusted P< 0.05) and
miRNAs that are not significant anymore following the adjust-
ment (below the line).
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can be found, in the online version, at https://doi.org/10.
1016/j.gpb.2018.06.001.
The role of predictive miRNAs in regulating programmed cell
death and MAP kinase
To gain insights into the biological processes involving the up-
and down-regulated miRNAs, we performed two different
enrichment analyses. First, we carried out a cutoff-free
miRNA pathway enrichment analysis that takes the rank of
each miRNA into account. Second, we performed a specific
pathway enrichment analysis for the 9 significant miRNAs in
comparison to all other remaining miRNAs. Details on both
approaches are provided in the Materials section.
With respect to the first analysis, miRNAs were sorted in
the descending order according to the levels of over-
expression in patients developing cancer, i.e., the first miRNA
in the sorted list was the miRNA whose expression was most
strongly increased. As robust criterion for the degree of up-
regulation, we computed the area under the receiver operator
characteristics (ROC) curve (AUC). We identified biochemical
categories predominantly associated with miRNAs at the top
of the sorted list. Of the more than 14,000 categories included
in the miRNA Enrichment Analysis and Annotation tool
(miEAA), 1966 pathways and gene ontologies weresignificantly associated with the development of cancer
(P< 0.05; the rank-sum based method implemented in
miEAA). miRNAs with the most significantly up-regulated
expression (Table S2) were associated with regulation of
MAP kinase activity, integrin signaling pathway, and focal
adhesion (P= 2.3  105). miRNAs with the most down-
regulated expression that were associated with these three
pathways were hsa-miR-200b-3p and hsa-miR-199b-5p. The
full list of significant pathways is provided in Supplementary
Data S2.
Since the aforementioned approach does not necessarily
focus on the most significant miRNAs but on the general rel-
evance of miRNAs in the pathways considered, we specifically
analyzed the biological categories of the 9 significant miRNAs
detected in the previous section. Of these 9, 5 miRNAs were
found in at least one significant pathway (P< 0.05; hypergeo-
metric test as implemented in miEAA). In detail, miR-548d-5p,
miR-320c, and miR-519d-3p are associated with the Gene
Ontology (GO) ‘‘lipid binding”. miR-517a-3p, miR-320e, and
miR-519d-3p are all located on chromosome 19 with miR-
517a-3p and miR-519d-3p belonging to the same miRNA clus-
ter and being co-located with a distance of around 10,000
bases. Both miR-320c and miR-519d-3p are involved in the
GO category ‘‘programmed cell death”. Figure 3 provides a
miRNA–target gene interaction network showing that four
genes, namely SRCAP, DCTN5, ULK1, and SEMA7A, are
targeted each by three of the nine miRNAs.
Down-regulation of miR-150 in patients without cancer history
In addition to the information whether COPD patients devel-
oped cancer, anamnestic data on previous cancers had also
been collected in COSYCONET (Figure 1). We performed
an analysis of variance (ANOVA) with four groups of patients
including (1) patients who had no cancer history nor developed
cancer, (2) patients who had no cancer history but developed
cancer, (3) patients with a cancer history who did not develop
cancer, and (4) patients who had a history of cancer and devel-
oped cancer.
We found a significant influence of cancer history on
miRNA expression levels. The expression changes described
above were frequently especially evident for patients without
previous cancer history as exemplified using miR-150-5p
(Figure 4A). Here, the down-regulation of miR-150-5p was
most significant in patients without previous cancer history
(Groups 3; P= 0.003; ANOVA).
This observation prompted us also to compare the
‘‘extreme” groups, i.e., COPD patients that had no history
of cancer and did not develop cancer (Group 1) with patients
that had a history of cancer and developed cancer (Group 4).
In this comparison, we observed a down-regulation in miRNA
expression in cancer patients with P values which were, how-
ever, two to three orders of magnitude lower than those of
the initial analysis as shown in Figure 4B. The two most signif-
icant miRNAs miR-409-3p and miR-133b had adjusted P val-
ues of 1.3  107. These analyses suggest that a cancer history
can have a substantial impact on molecular miRNA profiles
and should be included as confounding variable. Details for
expression of each miRNA in both groups along with the fold
change and the P values are presented in Table S3.
Figure 3 miRNA-target interaction network for the four core miRNAs
The graphic shows for the four core miRNAs miR-320e, miR-517a-3p, miR-519d-3p, and miR-320c the joint target genes from the
miRTarbase. miRNA nodes are colored in brown, genes targeted by two miRNAs are colored in blue and genes targeted by three
miRNAs are colored in green.
Figure 4 Box-Whisker and Volcano plots for miRNAs including the information of a cancer history
A. Box whisker plot for miR-150-5p for the four patient groups shown in Figure 1. Patients in Group 3 showed significantly decreased
expression of miR-150-5p. B. Volcano plot for the two extreme groups: Group 1 and Group 4. Green dots indicate miRNAs with higher
expression in blood samples from Group 1, while red dots represent miRNAs with higher expression in blood samples from Group 4
according to the unadjusted P< 0.05. All dots with unadjusted P  0.05 are colored in gray. The horizontal blue line separates miRNAs
that are significant following Benjamini–Hochberg adjustment (above the line; adjusted P< 0.05) and miRNAs that are not significant
anymore following the adjustment (below the line).
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Figure 5 qRT-PCR validation of the expression of three miRNAs
The graphic shows the CT values of expression in blood from
patients developing cancer (n = 31) and those not developing
cancer (n = 56) for the three miRNAs that were evaluated by
qRT-PCR. * indicates significant difference in miRNA expression
(P< 0.05; two-tailed t-test) between the two patient groups. n.s.,
non significant.
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cancer without known cancer history
To check whether combinations of miRNAs have the ability to
predict the development of cancer we next performed pair-wise
classifications with gradient-boosted trees using small sets of
2–13 miRNAs as described in the Methods section. While
the performance to predict a newly developing cancer in
patients who had a history of cancer was not significantly bet-
ter than random (accuracy of 50.5% using 8 miRNAs), it was
possible to successfully predict newly developing cancers in
patients without previous history of cancer. Since impact of
the observed accuracy (71.5%) is limited by the unbalanced
sample sizes, we also calculated the AUC value as a more
informative performance measure. As a result, we obtained
an AUC value of 74.7% using only two miRNAs, namely
miR-450a-5p and miR-200b-3p, the latter being among the
two most down-regulated miRNAs in the initial analysis.
The best classification performance with an accuracy of
85.0% and an AUC of 87.4% was reached between patients
who had a history of cancer and did not develop cancer
(Group 2) and patients who have no history of cancer but
developed cancer (Group 3) using three miRNAs (miR-450a-
5p, miR-4677-3p, and miR-9-3p). The detailed classification
results are presented in Table S4.
Validation of the microarray data using qRT-PCR
In order to validate the results obtained by microarray analy-
sis, especially the predominant down-regulation of the miRNA
expression, and to provide evidence that the down-regulation
is not a general artifact or bias in the microarrays due to nor-
malization, we performed qRT-PCR on a subset of samples
including all samples of patients that developed a new tumor
where enough material was left (31 of the original 33 cases)
and 56 random controls that did not develop a tumor. First,
we selected the aforementioned miR-150-5p, whose expression
was down-regulated 1.47 fold in the original microarrays (see
Table S1). In line with the microarray data, expression of
miR-150-5p was significantly decreased by 2.52 fold in patients
with future tumors compared to controls (P= 5.71  107).
Besides this clearly down-regulated miRNA, we chose two
candidates with lower fold changes (Table S1). The expression
of miR-631 (fold change in the microarray analysis was 1.02)
was 1.67 fold reduced in patients with future tumors as shown
in PCR. Likewise, the expression of miR-574-3p that was 1.28
–fold down-regulated in the microarrays was slightly decreased
by 1.1 fold as shown in PCR. Due to the smaller sample num-
ber in the validation, the down-regulation of the latter two
miRNAs was however not significant in the qRT-PCR analy-
sis. The RT-qPCR data are presented in Figure 5.
The limited influence of age/gender/smoking history and other
factors
We utilized clinical data of COSYCONET study to examine
potential confounding factors. Smoking history and age are
two risk factors that may have an influence on cancer and
COPD [28,29]. Although case and control cohort were similar
with respect to these factors (see Table 1), we analyzed whether
miRNAs correlated with age or individual smoking habits.None of the miRNAs was significantly linked to the number
of years of smoking, nor to the number of cigarettes per day,
nor to pack years (adjusted P> 0.05). There were, however,
differences in miRNA expression between current and former
smokers, most significantly for miR-92b-3p. Similarly, we
found differences between patients who never smoked versus
former or current smokers. Expression of 11 miRNAs was sig-
nificantly correlated with age and the strongest correlations
were found for miR-342-5p and miR-31-5p. Similarly, expres-
sion of three miRNAs was significantly associated with gender
with most strong association found for miR-1912. These find-
ings emphasize the need to match the groups with respect to
these confounders. miRNAs affected by the confounders
may either be excluded in building reliable statistical models
for predicting newly developed cancers or be taken into
account by using adjusted values for miRNA expression. All
P values are provided in Table S5.
miRNAs are correlated to other clinical factors relevant to lung
function
We additionally analyzed the potential dependence of miRNA
expression on other clinical information as coded in 84 param-
eters provided in the baseline description of COSYCONET
[27]. ANOVA was used to test the dependence of miRNA
expression on categorical features, whereas linear correlation
coefficients were used on non-categorical features (P values
are provided in Table S5). For most of the parameters, includ-
ing the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) spirometric categories, no miRNA remained statisti-
cally significant after adjustment for multiple testing. How-
ever, we found that expression of 19 miRNAs, most strongly
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distance following adjustment for multiple testing. Addition-
ally, expression of 3 miRNAs was found to be correlated with
the long term oxygen therapy (LTOT) oxygen volume (l/min),
comorbidity sarcoidosis, the diagnosis of atopic eczema, and
chronic venous insufficiency, respectively. The respective miR-
NAs were usually different from those identified to be relevant
for cancer development, and the effect sizes were moderate.
These results indicate that smoking status, age, gender, and
comorbidities have an influence on miRNA expression.
Nonetheless, the strongest associations were found for the
development of cancer, especially in the absence of previous
cancer.
Discussion
In the present study, we analyzed blood samples collected in
the COSYCONET COPD study. The large-scale collection
of samples from patients without cancer at baseline, but with
follow-up data, allowed to address the question of early diag-
nostic miRNA signatures for cancer. Limitations of the pre-
sent study include the nature of the cancer diagnosis, which
was patient-reported and the lack of information about the
type of cancer besides lung cancer.
A common challenge in high-throughput molecular mea-
surements is the low sampling density, i.e., the fact that many
more features (p) than individuals (n) are considered (p n
challenge), which requires an adjustment of significance levels.
One challenge with the present study is the imbalance between
patients not developing cancer and those developing cancer.
Since 33 cancer cases were available, one logical approach
would have been to select 33 controls. However, given the
above addressed p n challenge, this would likely not lead
to reliable results. In the present study, 2549 human miRNAs
were included compared to a number of 534 COPD patients.
About 6% of patients developed cancer within 54 months,
hence the groups were not balanced. Nonetheless, the effect
sizes were strong enough and concordant to our power calcu-
lation such that 9 of 269 nominally significant markers miR-
NAs remained significant following adjustment for multiple
testing. Furthermore, the current set-up with more non-
cancer cases than cancer cases more likely corresponds to a
realistic clinical setting than a mixture of 50% cases and
50% controls, especially if the signature will be applied to a
screening set up, in which case numbers are usually one to
two orders of magnitude below controls.
Our experimental methodology and distribution-based nor-
malization techniques do not allow to identify global pattern
alterations. The 9 most significant markers were all down-
regulated. As shown by the volcano plots in Figures 2 and 4,
there are also up-regulated miRNAs, suggesting that there is
no overarching or global down-regulation pattern.
Since lung cancer is among the frequently investigated can-
cer entities, it is not surprising that a large fraction of the
markers described in the present study has already been iden-
tified in other studies [30–32] but the heterogeneity of studies
(different blood collection devices, measurement platforms,
cohort characteristics) renders direct comparisons difficult.
Considering the challenges described above, an analysis for
specific cancer sub-types would not be feasible even with
detailed histological data of the patients.We applied two miRNA set enrichment analyses, one using
the set of nine significant miRNAs (two tailed adjusted P value
of the t-test) and one rank-based approach that considers the
ranking of all miRNAs measured in the study without using
hard cut-off values. As a result, we identified a network of 4
miRNAs including miR-517a-3p, miR-320e, miR-519d-3p,
and miR-320c, and 28 target genes including the central target
genes SRCAP, DCTN5, ULK1, and SEMA. The majority of
these genes and miRNAs have previously been correlated to
lung cancer. For example, a suppressed translation and degra-
dation of ULK1 represents a potential mechanism for autop-
hagy limitation in lung cancer [33], whereas miR-320c was
described as core predictor for lung and other cancers [34].
Different experimental approaches have been proposed for
miRNA classification [35]. In the present study, we experi-
enced a high performance in building prediction models using
gradient boosted trees combined with selecting features (miR-
NAs) according to their ANOVA F-values.
Altogether, we found an enriched fraction of markers that
were less expressed in lung cancer with specific functional cat-
egories including MAP kinase, integrin signaling, and focal
adhesion pathways. There were promising classification results
using miRNA signatures for several pair-wise classification
scenarios. To achieve more robust prediction, larger cohorts
of patients developing cancer are however required. According
to data from our miRNA tissue repository [36], the majority of
down-regulated miRNAs was not specific for lung tissue,
which is consistent with our previous data indicating a limited
overlap between blood cell-based profiles (e.g., from lympho-
cytes or red blood cells) with tissue-based profiles [37].
Using the prospective characteristics of the COSYCONET
study, we observed molecular differences between the COPD
patients later developing cancer and patients who did not
develop cancer, indicating that miRNA signatures from blood
have a potential to predict lung cancer in early stages, espe-
cially if patients had not suffered from cancer previously.
The analysis of a variety of clinical parameters revealed an
influence of some of these parameters on miRNA profiles,
which could affect their predictive power for lung cancer.
Although the application of miRNAs in clinical care still
bears substantial challenges [25], there is a steadily increasing
evidence supporting that miRNAs have a significant diagnostic
potential. Our study suggests such a potential for early detec-
tion or prediction of lung cancer in COPD patients. In addi-
tion to the validation using other technologies, such as qRT-
PCR presented in this study, a validation using an independent
cohort is the logical next step to provide further evidence for
the predictive power of the miRNA signatures discovered in
this study.
Materials and methods
Study subjects and set-up
We used the baseline and follow-up datasets of the COSYC-
ONET cohort study (visit 1), which is a prospective, multi-
center, observational study in Germany [27]. Between 2010
and 2013, 2741 COPD patients were included. In addition to
the baseline visit, follow-ups were scheduled at 6, 18, 36, and
54 months. At each visit, a large panel of assessments was per-
formed, such as clinical history, smoking history, spirometry,
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capacity, PAXGene blood sampling, 6-min walk distance,
electrocardiogram, and echocardiography. Patient-reported
physician-based diagnoses of cancer of any kind were used
to identify eligible individuals to be included in the study. Fur-
thermore, a control cohort of COPD patients not developing
cancer matched for age/sex/smoking history was included.
The biosamples used (PAXGene blood samples) were taken
from the baseline visit. The primary outcome measure was a
positive cancer diagnosis of any kind during the follow-up in
the COSYCONET study.
A sketch of the study design is presented in Figure 1. The
follow-up time for the occurrence of cancer was 54 months,
which is consistent with the study set up of COSYCONET.
Such long follow-up periods are reasonable since previous
analyses identified pre-cancerous miRNA signatures several
years prior to the cancer diagnosis [38].
Out of all 2741 cases recorded by COSYCONET, we ana-
lyzed 33 COPD patients that developed cancer during the
follow-up period. As for the numbers of controls, i.e., COPD
patients not developing cancer, the rational was as follows:
selecting 33 controls with a power of 0.95 at an alpha error rate
of 0.05 corresponds to an effect size of 0.9 for single miRNAs.
Since previous studies show that miRNAs have lower effect
sizes, we selected 500 controls yielding an effect size of 0.65
for single miRNAs. The control cohort was selected to keep
potentially confounding variables similar between cases and
controls (see Table 1).
Local ethics committee approved the study and all patients
contributing to the study provided written informed consent.
RNA isolation
RNA isolation was performed as described previously [39]. In
short, RNA from whole blood samples collected in PAXgene
Blood Tubes (BD Biosciences, Franklin Lakes, NJ) was iso-
lated using PAXgene Blood miRNA Kit (Qiagen, Hilden,
Germany) according to manufacturers’ instructions in a semi-
automated fashion using Qiacube robot (Qiagen) to ensure
reproducibility. RNA concentration was measured with
Nanodrop spectral photometer (ThermoFisher Scientific, Wal-
tham, MA) and RNA Integrity was assessed using RNA Nano
Bioanalyzer Kit (Agilent Technologies, Santa Clara, CA).
Microarray measurement
Considering the suggested substantial influence of library
preparation on high-throughput sequencing studies [40,41],
we profiled the miRNA expression in blood samples using
microarray analysis. miRNA expression measurements were
performed as described previously by using the Agilent
microarray system with the Human miRBase V21 microarrays
[36,42], containing 2549 mature human miRNAs. In short,
RNA was dephosphorylated and then labeled with Cy3-pCp.
Labeled RNA samples were hybridized to the arrays for 20 h
at 55 C. After washing and drying, arrays were scanned in
an Agilent microarray scanner at 3-mm resolution in double-
path mode. Raw expression values were extracted using Fea-
ture Extraction Software (Agilent Technologies, Santa Clara,
CA). Altogether, we selected 580 patients from COSYCONET.
For 534 samples, both, the RNA extraction and microarraymeasurement yielded high-quality results, while 46 samples
failed quality control, i.e., either RNA concentration or RNA
integrity number (RIN) value is too low. These samples were
excluded prior to further measurement or statistical analysis.
The microarray data are available upon request.
Reverse transcription-quantitative PCR
RT-qPCR was performed using the miScript PCR system (Qia-
gen, Hilden, Germany). For a subset of 87 samples (31 with
future tumor and 56 controls) we determined the expression
levels of three miRNAs, i.e., miR-150-5p, miR-574-3p, and
miR-631. RNU6B and SNORD48 were used as endogenous
controls. In detail, 100 ng total RNA was reversely transcribed
using miScript RT II kit, and 1 ng cDNA was used for qPCR
using miScript SYBR Green reagent and respective miScript
Primers (Qiagen) on a StepOnePlus cycler (Applied Biosystems,
Foster City, CA). All reactions were set up in duplicates. Data
were analyzed using StepOneSoftware (Applied Biosystems).
Statistical analysis
All computations were performed using R (version 3.0.2) based
on scripts developed for previous projects [39]. Following back-
ground subtraction and computation of the expression inten-
sity of a miRNA by calculating the median of all replicates of
that miRNA on each microarray, data were normalized using
quantil normalization. To test whether miRNAs follow a nor-
mal or a log-normal distribution, ShapiroWilk tests on the nor-
malized and log-normalized data were computed. Since in both
cases miRNAs that were not normally (or log-normally) dis-
tributed were discovered, we applied besides the parametric
tests (for categorical features, two-tailed t-tests and ANOVA
were performed) also non-parametric tests (here, the rank-
based unpaired two-tailed Wilcoxon–Mann–Whitney test was
applied). Both hypothesis tests, t-test and Wilcoxon–Mann–
Whitney test, showed a high correlation to each other (correla-
tion of 0.76, P< 1016). In the manuscript, we focus on the
more common t-test P values but because of the challenges
described above and for the sake of completeness, all raw and
adjusted P values computed by the t-test and the Wilcoxon–
Mann–Whitney test are provided in Table S1). In case of
multiple ties, P values were validated by using an exact imple-
mentation considering ties in EDISON-WMW [43].
For continuous features, Pearson correlation coefficients
were computed. For the comparison of age, pack years, smoking
status, and gender between the two cohorts, t-tests, contingence
tables, and Fisher’s exact 2  2 test were used. To draw infer-
ences on the involved biochemical pathways, the miEAA anno-
tation [44], which is built on the well-known GeneTrail
framework [45], was employed. As most other pathway analysis
tools, miEAA and GeneTrail support not only a gene set-based
analysis using, e.g., Fisher’s test or the hypergeometric test, but
also cutoff-free analyses. In the first case, the significant miR-
NAs could be compared to the non-significant miRNAs in our
study and we would ask whether the significant miRNAs accu-
mulate on one or several pathways. In this case, a miRNA with
P= 0.049 would be considered while amiRNAwithP= 0.051
(having basically the same information content) would belong
to the background set. For this reason, we also implemented
and applied cutoff-free analysis. The miRNAs are ranked by
170 Genomics Proteomics Bioinformatics 16 (2018) 162–171their P values and the sorted list of miRNAs is processed from
top to bottom. Whenever a miRNA belonging to a pathway is
found, a running sum is increased by (m–l) and otherwise the
running sum is decreased by l. Here,m is the number of all miR-
NAs and l is the number of miRNAs on the current pathway.
The P value for a pathway computes as the total number of all
running sums exceeding the maximum value of the actual run-
ning sum. ThisP value is calculated by enumerating all potential
distributions in an efficient manner relying on dynamic pro-
gramming [46]. Using miEAA, over 14,000 pathways and other
categories were tested sequentially using the two previously
described approaches. Targeted gene–miRNA interactionswere
assessed using miRTargetLink [47].
If not mentioned explicitly, all P values were subjected to
adjustment for multiple testing. The level of significance was
assumed at P= 0.05 and significance values were adjusted
for multiple testing if not mentioned explicitly.
Machine learning
Predictions models were created based on the quantil normal-
ized expression values of the miRNAs. All models were built
using the gradient boosted tree implementation of the
LightGBM framework. To account for the class imbalance,
we weighted the classes according to their ratios. Hyperparam-
eter tuning of the number of leaves, trees, and features was
applied via grid search in a 5-time repeated 5-fold cross-
validation. In this procedure only features with the highest
ANOVA F-value were selected. All reported performance val-
ues refer to the cross-validation metrics. The final reported fea-
tures were determined using the best performing model on the
whole dataset.
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